{"id":121113,"date":"2025-12-30T17:59:04","date_gmt":"2025-12-30T17:59:04","guid":{"rendered":"https:\/\/www.europesays.com\/se\/121113\/"},"modified":"2025-12-30T17:59:04","modified_gmt":"2025-12-30T17:59:04","slug":"novo-nordisk-bekraftar-sankta-wegovy-priser-i-kina-eli-lilly-foljer-i-samma-spar-reuters","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/121113\/","title":{"rendered":"Novo Nordisk bekr\u00e4ftar s\u00e4nkta Wegovy-priser i Kina, Eli Lilly f\u00f6ljer i samma sp\u00e5r &#8211; Reuters"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Danska l\u00e4kemedelsbolaget Novo Nordisk bekr\u00e4ftar s\u00e4nkta priser p\u00e5 fetmal\u00e4kemedlet Wegovy i Kina, efter att lokala finanstidningen Yicai varit f\u00f6rst ut att rapportera om detta. \u00c4ven rivalen Eli Lilly f\u00f6ljer upp detta med l\u00e4gre priser p\u00e5 sitt motsvarande l\u00e4kemedel Mounjaro, enligt ett inl\u00e4gg fr\u00e5n ett lokalt sjukhus i Nanjing p\u00e5 Wechat.\n <\/p>\n<p>Novo Nordisk bekr\u00e4ftar prisjusteringen till nyhetsbyr\u00e5n Reuters.\n <\/p>\n<p>\u201dVi tror att denna prisjustering i Kina kommer att bidra till att ytterligare lindra behandlingsb\u00f6rdan f\u00f6r patienterna och f\u00f6rb\u00e4ttra deras livskvalitet\u201d, s\u00e4ger bolaget.\n <\/p>\n<p>Novo Nordisk sade inget om hur mycket priserna s\u00e4nks. Enligt Yicai har dock priserna s\u00e4nkts f\u00f6r de tv\u00e5 h\u00f6gsta doserna till 987 respektive 1 284 yuan, motsvarande 1 290 och 1 675 kronor, i vissa provinser.\n <\/p>\n<p>Eli Lilly har inte \u00e5terkommit med en kommentar till Reuters.\n <\/p>\n<p>\u00d6ver 65 procent av Kinas befolkning p\u00e5 cirka 1,4 miljarder kan vara \u00f6verviktiga eller feta \u00e5r 2030, vilket g\u00f6r det till en snabbt v\u00e4xande marknad f\u00f6r bantningsl\u00e4kemedel.<br \/>\n <br class=\"col-start-2\"\/><\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Reno Santic<br \/>\n <br class=\"col-start-2\"\/><br \/>\n Nyhetsbyr\u00e5n Finwire<br \/>\n <br class=\"col-start-2\"\/><br \/>\n <a class=\"twitter-timeline\" data-width=\"1200\" data-height=\"1000\" data-dnt=\"true\" href=\"https:\/\/twitter.com\/Finwire?ref_src=twsrc%5Etfw\" rel=\"nofollow noopener\" target=\"_blank\">Tweets by Finwire<\/a><script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><br \/>\n <br class=\"col-start-2\"\/><br \/>\n newsroom@finwire.se<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\"><a class=\"text-primary-90 underline hover:text-primary-110 hover:no-underline\" rel=\"noopener noreferrer nofollow\" target=\"_blank\" href=\"https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/novo-cuts-wegovy-prices-some-chinese-provinces-local-media-reports-2025-12-29\/\">L\u00e4s mer p\u00e5 Finwire<\/a><\/p>\n<p><script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script><\/p>\n","protected":false},"excerpt":{"rendered":"Danska l\u00e4kemedelsbolaget Novo Nordisk bekr\u00e4ftar s\u00e4nkta priser p\u00e5 fetmal\u00e4kemedlet Wegovy i Kina, efter att lokala finanstidningen Yicai varit&hellip;\n","protected":false},"author":2,"featured_media":119816,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[65],"tags":[72,70,71,34,31,33,32,30],"class_list":{"0":"post-121113","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ekonomi","8":"tag-business","9":"tag-economy","10":"tag-ekonomi","11":"tag-se","12":"tag-svenska","13":"tag-sverige","14":"tag-sweden","15":"tag-swedish"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/115809823247613325","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/121113","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=121113"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/121113\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/119816"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=121113"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=121113"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=121113"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}